BNP Paribas Financial Markets’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $335K | Buy |
157,248
+127,433
| +427% | +$219K | ﹤0.01% | 3977 |
|
|
2026
Q1 | $50.4K | Sell |
29,815
-233,592
| -89% | -$1.02M | ﹤0.01% | 4689 |
|
|
2025
Q4 | $1.36M | Buy |
263,407
+252,797
| +2,383% | +$1.3M | ﹤0.01% | 2895 |
|
|
2025
Q3 | $55.4K | Buy |
10,610
+2,859
| +37% | +$14.9K | ﹤0.01% | 4558 |
|
|
2025
Q2 | $29.7K | Sell |
7,751
-19,342
| -71% | -$50K | ﹤0.01% | 4448 |
|
|
2025
Q1 | $156K | Buy |
27,093
+20,738
| +326% | +$123K | ﹤0.01% | 3848 |
|
|
2024
Q4 | $31.7K | Sell |
6,355
-7,874
| -55% | -$40.4K | ﹤0.01% | 4586 |
|
|
2024
Q3 | $76.7K | Buy |
14,229
+10,201
| +253% | +$48.6K | ﹤0.01% | 3528 |
|
|
2024
Q2 | $13.3K | Sell |
4,028
-21,250
| -84% | -$83.2K | ﹤0.01% | 3696 |
|
|
2024
Q1 | $82.7K | Buy |
25,278
+4,797
| +23% | +$15.8K | ﹤0.01% | 3483 |
|
|
2023
Q4 | $71.9K | Sell |
20,481
-47,460
| -70% | -$146K | ﹤0.01% | 3478 |
|
|
2023
Q3 | $454K | Buy |
67,941
+8,122
| +14% | +$60.3K | ﹤0.01% | 2769 |
|
|
2023
Q2 | $502K | Buy |
+59,819
| New | +$589K | ﹤0.01% | 2579 |
|
|
2023
Q1 | – | Sell |
-53
| Closed | -$369 | – | 3852 |
|
|
2022
Q4 | $369 | Sell |
53
-593
| -92% | -$3.39K | ﹤0.01% | 3884 |
|
|
2022
Q3 | $3.45K | Sell |
646
-1,554
| -71% | -$9.32K | ﹤0.01% | 4289 |
|
|
2022
Q2 | $8.78K | Sell |
2,200
-5,268
| -71% | -$18.1K | ﹤0.01% | 3760 |
|
|
2022
Q1 | $33.2K | Sell |
7,468
-2,468
| -25% | -$9.83K | ﹤0.01% | 3639 |
|
|
2021
Q4 | $39.7K | Buy |
9,936
+1,272
| +15% | +$9.7K | ﹤0.01% | 3777 |
|
|
2021
Q3 | $76.1K | Buy |
8,664
+6,821
| +370% | +$62.6K | ﹤0.01% | 3385 |
|
|
2021
Q2 | $20.9K | Sell |
1,843
-30,049
| -94% | -$361K | ﹤0.01% | 3521 |
|
|
2021
Q1 | $379K | Buy |
+31,892
| New | +$367K | ﹤0.01% | 2729 |
|
|
2020
Q4 | – | Sell |
-1,257
| Closed | -$9.31K | – | 4144 |
|
|
2020
Q3 | $9.31K | Sell |
1,257
-36,326
| -97% | -$235K | ﹤0.01% | 3969 |
|
|
2020
Q2 | $157K | Buy |
37,583
+30,484
| +429% | +$111K | ﹤0.01% | 2587 |
|
|
2020
Q1 | $17.5K | Buy |
7,099
+3,287
| +86% | +$14.8K | ﹤0.01% | 3936 |
|
|
2019
Q4 | $22.1K | Buy |
3,812
+378
| +11% | +$2.18K | ﹤0.01% | 3968 |
|
|
2019
Q3 | $18.1K | Buy |
3,434
+856
| +33% | +$4.61K | ﹤0.01% | 3987 |
|
|
2019
Q2 | $15.5K | Sell |
2,578
-1,812
| -41% | -$13.6K | ﹤0.01% | 3988 |
|
|
2019
Q1 | $39.6K | Buy |
+4,390
| New | +$37.3K | ﹤0.01% | 3634 |
|
|
2018
Q4 | – | Sell |
-521
| Closed | -$7.19K | – | 4332 |
|
|
2018
Q3 | $7.19K | Hold |
521
| – | – | ﹤0.01% | 3897 |
|
|
2018
Q2 | $4.14K | Buy |
+521
| New | +$4.16K | ﹤0.01% | 4147 |
|
Other funds holding ALDX
KCM
KCM
6CM
BNP Paribas Financial Markets's ALDX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Aldeyra Therapeutics (ALDX) stake by 427% in Q2 2026, buying an estimated $219K and bringing the position to 157,248 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #3977.
BNP Paribas Financial Markets first reported a position in ALDX in Q2 2018 and has held it in 30 quarters since. The position peaked at $1.36M in Q4 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.
- BNP Paribas Financial Markets held 157,248 shares of Aldeyra Therapeutics worth $335K as of Q2 2026.
- BNP Paribas Financial Markets bought 127,433 Aldeyra Therapeutics shares in Q2 2026, an estimated $219K.
- Aldeyra Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3977 holding.
- BNP Paribas Financial Markets first reported a position in Aldeyra Therapeutics in Q2 2018 and has held it in 30 quarters since.
- BNP Paribas Financial Markets's Aldeyra Therapeutics position peaked at $1.36M in Q4 2025.
- 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.